Cell line name |
IGROV-1/CP |
Synonyms |
IGROV-1-CP; IGROV1CP |
Accession |
CVCL_IQ21 |
Resource Identification Initiative |
To cite this cell line use: IGROV-1/CP (RRID:CVCL_IQ21) |
Comments |
Population: Caucasian. Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Omics: Deep proteome analysis. Omics: Transcriptome analysis by RNAseq. Derived from site: In situ; Ovary; UBERON=UBERON_0000992. |
Sequence variations |
- Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line).
- Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); ClinVar=VCV001756201; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line).
|
Disease |
Ovarian endometrioid adenocarcinoma (NCIt: C7979) Endometrioid carcinoma of ovary (ORDO: Orphanet_454723) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_1304 (IGROV-1) |
Sex of cell |
Female |
Age at sampling |
47Y |
Category |
Cancer cell line |
Publications | PubMed=16319398; DOI=10.1074/mcp.M500140-MCP200 Stewart J.J., White J.T., Yan X.-W., Collins S.J., Drescher C.W., Urban N.D., Hood L.E., Lin B.-Y. Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol. Cell. Proteomics 5:433-443(2006) PubMed=23913215; DOI=10.1007/978-1-62703-547-7_12 Li L.-S., Liu J., Yu W., Lou X.-Y., Huang B.-D., Lin B.-Y. Deep transcriptome profiling of ovarian cancer cells using next-generation sequencing approach. Methods Mol. Biol. 1049:139-169(2013) PubMed=27561551; DOI=10.1038/ncomms12645 Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat. Commun. 7:12645.1-12645.14(2016) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_IQ21
|
Encyclopedic resources |
Wikidata; Q54897385
|
Proteomic databases |
PRIDE; PXD003668
|
Entry history |
Entry creation | 03-Mar-2017 |
Last entry update | 05-Oct-2023 |
Version number | 17 |
---|